Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Champlin

Showing results (101-110 of 218) with videos related to

Pageof 22
Sort By:
American Journal of Hematology|April 30, 2014
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemiaOhad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, et al.
Clinical Lymphoma & Myeloma|September 26, 2009
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib eraRichard Champlin, Marcos de Lima, Partow Kebriaei, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2019
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning RegimensHossein Maymani, Paul Lin, Rima M Saliba, et al.
Blood|May 15, 2010
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemiaFarhad Ravandi, Susan O'Brien, Deborah Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation FailureUri Rozovski, Ohad Benjamini, Preetesh Jain, et al.
Scientific Reports|February 23, 2012
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapyColleen M O'Connor, Sabina Sheppard, Cassie A Hartline, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2012
Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remissionBetul Oran, Uday Popat, Gabriella Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 3, 2004
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantationDaniel R Couriel, Rima M Saliba, Sergio Giralt, et al.
American Journal of Hematology|December 11, 2022
Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remissionOren Pasvolsky, Rima M Saliba, Celina Ledesma, et al.
American Journal of Hematology|July 19, 2020
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemiaYasmin Abaza, Hagop Kantarjian, Yasmin Alwash, et al.
Pageof 22

Showing results (101-110 of 218) with videos related to

Sort By:
Pageof 22
American Journal of Hematology|April 30, 2014
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemiaOhad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, et al.
Clinical Lymphoma & Myeloma|September 26, 2009
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib eraRichard Champlin, Marcos de Lima, Partow Kebriaei, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 15, 2019
Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning RegimensHossein Maymani, Paul Lin, Rima M Saliba, et al.
Blood|May 15, 2010
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemiaFarhad Ravandi, Susan O'Brien, Deborah Thomas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation FailureUri Rozovski, Ohad Benjamini, Preetesh Jain, et al.
Scientific Reports|February 23, 2012
Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapyColleen M O'Connor, Sabina Sheppard, Cassie A Hartline, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 18, 2012
Significance of persistent cytogenetic abnormalities on myeloablative allogeneic stem cell transplantation in first complete remissionBetul Oran, Uday Popat, Gabriella Rondon, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 3, 2004
Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantationDaniel R Couriel, Rima M Saliba, Sergio Giralt, et al.
American Journal of Hematology|December 11, 2022
Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remissionOren Pasvolsky, Rima M Saliba, Celina Ledesma, et al.
American Journal of Hematology|July 19, 2020
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemiaYasmin Abaza, Hagop Kantarjian, Yasmin Alwash, et al.
Pageof 22